Patent search ap:("Oryzon Genomics S.A.") AND inv:"Alberto ORTEGA MUÑOZ" Page 1

1.

发明申请
(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS 有权
Title translation: （HETERO）ARYL CYPOPRAMLAMINE COMPOUNDS AS LSD1 INHIBITORS

公开(公告)号：US20170008844A1

公开(公告)日：2017-01-12

申请号：US15271772

申请日：2016-09-21

Applicant: Oryzon Genomics, S.A.

Inventor： Alberto ORTEGA MUÑOZ , Matthew Colin Thor FYFE , Marc MARTINELL PEDEMONTE , Maria de los Àngeles ESTIARTE MARTINEZ , Nuria VALLS VIDAL , Guido KURZ , Julio Cesar CASTRO PALOMINO LARIA

IPC: C07D211/58 , C07D405/12 , C07D309/04 , C07D211/56 , C07D207/14 , C07D205/04 , C07D451/04 , C07D221/20 , C07D215/42 , C07D401/12 , C07D417/12 , C07D401/04 , C07D335/02 , C07D223/12 , C07D211/26

CPC classification number: C07D211/58 , C07D205/04 , C07D207/09 , C07D207/14 , C07D209/96 , C07D211/26 , C07D211/56 , C07D215/42 , C07D221/20 , C07D223/12 , C07D309/04 , C07D309/14 , C07D335/02 , C07D401/04 , C07D401/12 , C07D405/12 , C07D417/12 , C07D451/04

Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

Abstract translation: 本发明涉及（异）芳基环丙胺化合物，特别包括本文所述和定义的式I化合物及其在治疗中的用途，包括例如治疗或预防癌症，神经疾病或病症，或病毒感染。

2.

发明申请
CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS 有权

公开(公告)号：US20160052865A1

公开(公告)日：2016-02-25

申请号：US14640395

申请日：2015-03-06

Applicant: Oryzon Genomics, S.A.

Inventor： Matthew Colin Thor FYFE , Alberto ORTEGA MUÑOZ , Julio CASTRO-PALOMINO LARIA , Marc MARTINELL PEDEMONTE , Maria de los Angeles ESTIARTE-MARTINEZ , Nuria VALLS VIDAL

IPC: C07C211/40 , C07C311/09 , C07C311/08 , C07C255/59 , C07C215/64 , C07C311/21

CPC classification number: C07C211/40 , C07B2200/07 , C07C215/64 , C07C217/74 , C07C255/53 , C07C255/54 , C07C255/59 , C07C311/08 , C07C311/09 , C07C311/21 , C07C2601/02 , C07D213/38 , C07D213/40 , C07D213/42 , C07D213/56 , C07D213/57 , C07D213/64 , C07D239/26 , C07D277/28 , C07D333/20 , C07D401/04 , C07D401/10 , C07D405/04 , C07D405/10 , C07D409/04 , C07D409/10

Abstract: The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection.

3.

发明申请
1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS 审中-公开

公开(公告)号：US20200339569A1

公开(公告)日：2020-10-29

申请号：US16768931

申请日：2018-12-05

Applicant: Oryzon Genomics, S.A.

Inventor： Elena CARCELLER GONZÁLEZ , Alberto ORTEGA MUÑOZ , Jorge SALAS SOLANA

IPC: C07D471/04 , C07D413/14

Abstract: The invention relates to compounds of Formula (I) as described herein, useful as histone deacetylase 6 (HDAC6) inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy.

4.

发明申请
(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS 审中-公开

公开(公告)号：US20180079709A1

公开(公告)日：2018-03-22

申请号：US15497556

申请日：2017-04-26

Applicant: Oryzon Genomics S.A.

Inventor： Alberto ORTEGA MUÑOZ , Matthew Colin Thor Fyfe , Marc Martinell Pedemonte , Maria de los Àngeles Estiarte Martinez , Nuria Valls Vidal , Guido Kurz , Julio Cesar Castro Palomino Laria

IPC: C07C211/36 , C07D333/20 , C07C273/00 , C07D213/57 , C07D213/73 , C07D231/56 , C07C213/00 , C07C215/64 , C07C217/74 , C07C211/40 , C07C217/54 , C07C215/46 , C07C311/21 , C07C311/08 , C07C273/18 , C07C209/28 , C07C211/38 , C07C269/00 , C07D213/74 , C07D307/52 , C07D213/38 , C07D213/30 , C07D295/26 , C07D295/135 , C07D295/096 , C07D277/28 , C07D207/14 , C07D231/12 , C07C275/26 , C07C271/24

CPC classification number: C07C211/36 , C07B2200/07 , C07C209/28 , C07C211/37 , C07C211/38 , C07C211/40 , C07C213/00 , C07C215/46 , C07C215/64 , C07C217/54 , C07C217/74 , C07C269/00 , C07C271/24 , C07C273/00 , C07C273/18 , C07C275/26 , C07C311/08 , C07C311/21 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07C2602/08 , C07D207/14 , C07D213/30 , C07D213/38 , C07D213/57 , C07D213/73 , C07D213/74 , C07D231/12 , C07D231/56 , C07D277/28 , C07D295/096 , C07D295/135 , C07D295/26 , C07D307/52 , C07D333/20

Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

5.

发明申请
1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS 有权

公开(公告)号：US20230026909A1

公开(公告)日：2023-01-26

申请号：US17650561

申请日：2022-02-10

Applicant: Oryzon Genomics, S.A.

Inventor： Elena CARCELLER GONZÁLEZ , Alberto ORTEGA MUÑOZ , Jorge SALAS SOLANA

IPC: C07D471/04 , C07D413/14

Abstract: The invention relates to compounds of Formula (I) as described herein, useful as histone deacetylase 6 (HDAC6) inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy.

6.

发明申请
3-(2-(HETEROARYL)-PYRIDIN-4-YL)-5-(TRIFLUOROMETHYL)-1,2,4-OXADIAZOLE DERIVATIVES AS HDAC6 INHIBITORS 有权

公开(公告)号：US20220298156A1

公开(公告)日：2022-09-22

申请号：US17596048

申请日：2020-06-05

Applicant: ORYZON GENOMICS, S.A.

Inventor： Elena CARCELLER GONZÁLEZ , Alberto ORTEGA MUÑOZ , Jorge SALAS SOLANA

IPC: C07D471/04

Abstract: The invention relates to compounds as described herein, useful as histone deacetylase 6 (HDAC6) inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy.

7.

发明申请
ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE 审中-公开

公开(公告)号：US20180127406A1

公开(公告)日：2018-05-10

申请号：US15623866

申请日：2017-06-15

Applicant: Oryzon Genomics S.A.

Inventor： Alberto ORTEGA MUÑOZ , Matthew Colin Thor FYEE , Marc MARTINELL PEDEMONTE , Iñigo TIRAPU FERNANDEZ DE LA CUESTA , Maria de los Ángeles ESTIARTE MARTINEZ

IPC: C07D417/12 , A61K31/422 , C07D213/73 , A61K31/433 , C07D285/08 , C07D285/135 , C07D413/12 , C07D401/12 , C07D285/12 , C07D277/40 , C07D271/113 , C07D271/07 , C07D263/48 , C07D261/14 , C07D253/07 , C07D241/20 , C07D239/42 , C07D237/20 , A61K31/4245

CPC classification number: C07D417/12 , A61K31/422 , A61K31/4245 , A61K31/433 , A61K31/4439 , A61K31/506 , C07D213/73 , C07D237/20 , C07D239/42 , C07D241/20 , C07D253/07 , C07D261/14 , C07D263/48 , C07D271/07 , C07D271/113 , C07D277/40 , C07D285/08 , C07D285/12 , C07D285/135 , C07D401/12 , C07D413/12

Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).

8.

发明申请
PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE 审中-公开
Title translation: 苯甲酰胺衍生物及其医学用途

公开(公告)号：US20160045456A1

公开(公告)日：2016-02-18

申请号：US14627333

申请日：2015-02-20

Applicant: ORYZON GENOMICS S.A.

Inventor： Nathalie GUIBOURT , Alberto ORTEGA MUÑOZ , Julio CASTRO-PALOMINO LARIA

IPC: A61K31/137 , A61K31/277 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/426 , A61K31/381 , A61K31/47 , A61K31/44 , A61K31/4045 , A61K31/343 , A61K31/36 , A61K31/357 , A61K31/353 , A61K31/4245 , C12Q1/26 , A61K31/14

CPC classification number: A61K31/137 , A61K31/14 , A61K31/277 , A61K31/343 , A61K31/353 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/4045 , A61K31/4245 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , C07C211/40 , C07C217/58 , C07C217/74 , C07C255/58 , C07C2601/02 , C07D213/38 , C07D213/61 , C07D277/28 , C07D333/20 , C07D333/28 , C12Q1/26 , G01N2500/04 , G01N2500/20

Abstract: The present invention relates to phenylcyclopropylamine derivatives. In particular, pharmaceutical compositions comprising phenylcyclopropylamine derivatives are provided. The compounds of this invention can, inter alia, be used for the treatment and the prevention of cancer as well as neurodegenerative diseases or disorders.

Abstract translation: 本发明涉及苯基环丙基胺衍生物。特别地，提供了包含苯基环丙胺衍生物的药物组合物。本发明的化合物尤其可用于治疗和预防癌症以及神经变性疾病或病症。

9.

发明申请
METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR 有权

公开(公告)号：US20220389478A1

公开(公告)日：2022-12-08

申请号：US17644604

申请日：2021-12-16

Applicant: Oryzon Genomics S.A.

Inventor： Elena CARCELLER GONZÁLEZ , Tamara MAES , Cristina MASCARO CRUSAT , Alberto ORTEGA MUÑOZ

IPC: C12Q1/26 , C07D495/04 , G01N33/58

Abstract: The invention relates to methods to determine KDM1A target engagement and chemoprobes useful therefor. In particular, the invention relates to non-peptidic KDM1A chemoprobes carrying a tag or label that can be used to assess KDM1A target engagement in cells and tissues. These chemoprobes can also be used to identify KDM1A interacting factors and analyze expression levels of KDM1A.